CD274 and nasopharyngeal carcinoma: In addition, this study showed that the proportion of patients who responded was higher among those with PD-L1 positive tumors than those with PD-L1-negative tumors by a descriptive analysis, suggesting nivolumab has promising anti-tumor activity in NPC and hypothesizing local tissue PD-L1 expression as a predictor of nivolumab treatment response.18